Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 161

Sort by

Sort Order Select

Journal Articles

Bleeding Risk in Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies

Yimin Pearl Wang, BSc, Rohan Kehar, MDMSc,FRCPC, Alla Iansavitchene, BSc, Alejandro Lazo-Langner, MD MSc

Blood (2019) 134 (Supplement_1): 3672.

https://doi.org/10.1182/blood-2019-123870

Published: 2019

Journal Articles

Efficacy and Safety of Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism

Renata Almeida Sa, MSc, BSc, Fatimah Al-Ani, MD MRCP, Alejandro Lazo-Langner, MD MSc, Martha L Louzada, MDMSc

Blood (2019) 134 (Supplement_1): 3675.

https://doi.org/10.1182/blood-2019-121765

Published: 2019

Journal Articles

Effectiveness and Safety of Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Patients with Active Cancer Therapy and Non Valvular Atrial Fibrillation

Pável E Olivera, MD, César A Velasquez, MD, Desirée Campoy, MD, Gonzalo Artaza, MD, Tania Canals, MD, Katia Flores, MD, Silvia Ruiz, MD, Alessandra Comai, MD, Erik A Johansson, MD, Gabriela S Ene, MD PhD, Gabriela Bastidas, MD, Maricel Subira, MD PhD, Jorge Sierra, MD, Ramón Salinas, MD PhD

Blood (2019) 134 (Supplement_1): 3661.

https://doi.org/10.1182/blood-2019-128300

Published: 2019

Journal Articles

Efficacy and Safety of Direct Oral Anticoagulants in Patients with Cirrhosis— Single Institution Experience

Kamila I. Cisak, MD, Dennis Asante, MS, Diane E. Grill, MS, Aneel A. Ashrani, MD, M.S.

Blood (2018) 132 (Supplement 1): 2525.

https://doi.org/10.1182/blood-2018-99-117607

Published: 2018

Journal Articles

Risk of Subsequent Thrombosis in Patients with Isolated Heparin-Induced Thrombocytopenia

Heather R Wolfe, MD, Yu-Min Shen, MD

Blood (2018) 132 (Supplement 1): 3566.

https://doi.org/10.1182/blood-2018-99-117629

Published: 2018

Journal Articles

Heparin Vs Direct Thrombin Inhibitors in Patients with Previous HIT Undergoing Cardiothoracic Surgery: The Cleveland Clinic Experience

Daniel S Carlson, DO, Keith R. McCrae, MD, Shruti Chaturvedi, MBBS,MS

Blood (2018) 132 (Supplement 1): 425.

https://doi.org/10.1182/blood-2018-99-115375

Published: 2018

Journal Articles

Comparison of Rivaroxaban with Argatroban in Heparin Induced Thrombocytopenia Using Historical Controls : A Case-Control Study

Vivek Suresh Modi, MBBS, Karan Jatwani, MBBS, Sridevi Rajeeve, MD, Gaurav Kakked, MBBS, MS, Hardikumar Patel, mbbs, Dhrubajyoti Bandyopadhyay, MBBS, MD, Siva Krishna Mannem, MBBS

Blood (2018) 132 (Supplement 1): 4996.

https://doi.org/10.1182/blood-2018-99-120364

Published: 2018

Journal Articles

Yearly Percent Incidence of Suspected Novel Oral Anticoagulant Interference on Thrombophilia Testing: A Nine Year Experience at a Reference Coagulation Laboratory

Edward C.C. Wong, MD MA, Laura A. Worfolk, PhD, Jeffrey S. Dlott, MD

Blood (2018) 132 (Supplement 1): 4819.

https://doi.org/10.1182/blood-2018-99-112972

Published: 2018

Journal Articles

Risk Factors for Thrombosis in the Neonatal Intensive Care Unit: Analysis of a Large National Database

Uttara Nag, MD, Greenberg Rachel, MD MHS, Harold J Leraas, BS, MA, Candice Roberts, MD, Reed Kamyszek, BS, Elisabeth Tracy, MD

Blood (2017) 130 (Supplement 1): 3351.

https://doi.org/10.1182/blood.V130.Suppl_1.3351.3351

Published: 2017

Journal Articles

Measuring the Anticoagulation Effects of Exosite I Thrombin Inhibitors: Utility and Limitations of Clotting Assays, Thromboelastography, and Calibrated Automated Thrombography

Matthew Bunce, PhD, Zheng Huang Devine, PhD, Madhu Chintala, PhD

Blood (2017) 130 (Supplement 1): 1115.

https://doi.org/10.1182/blood.V130.Suppl_1.1115.1115

Published: 2017

Journal Articles

HIT Diagnosis: A Proposed New Definition for Clinical Research

Parisa R Khalighi, BS, David A Garcia, MD, Anand Padmanabhan, MD PhD, Bethany T Samuelson Bannow, MD

Blood (2017) 130 (Supplement 1): 3621.

https://doi.org/10.1182/blood.V130.Suppl_1.3621.3621

Published: 2017

Journal Articles

Impact of Systems-Based Hematologists in Maintaining a HIT Program Using Continuous Clinical Audit and Education in an Academic Medical Center

Ming Yeong Lim, MBBChir, Caroline Dupre Vaughn, RN, Alice Boylan, MD, Charles Greenberg, MD

Blood (2017) 130 (Supplement 1): 4658.

https://doi.org/10.1182/blood.V130.Suppl_1.4658.4658

Published: 2017

Journal Articles

A Simulation Analysis to Evaluate the Effect of Prospective Biomarker Testing on Progression-Free Survival (PFS) in DLBCL

Edith Szafer-Glusman, Juan Liu, Franklin V. Peale, Jr., Thalia A. Farazi, Jill Ray, Carsten Horn, Mikkel Z. Oestergaard, Martin Kornacker, Laurie H. Sehn, MDMPH, Günter Fingerle-Rowson, Jeffrey M. Venstrom, Michelle Byrtek, Elizabeth Punnoose

Blood (2017) 130 (Supplement 1): 419.

https://doi.org/10.1182/blood.V130.Suppl_1.419.419

Published: 2017

Journal Articles

HIT the price point with fondaparinux

Nathan T. Connell

Blood (2016) 128 (26): 3019–3020.

https://doi.org/10.1182/blood-2016-11-750513

Published: 2016

Journal Articles

Use of "Big Data" to Define Disease Burden, Complication Rates and Healthcare Costs in Patients with Heparin Induced Thrombocytopenia (HIT)

Binod Dhakal, MDMS, Parameswaran Hari, MBBS, MD MRCP, Lisa Rein, MS, Raphael Fraser, PhD, Anand Padmanabhan, MBBS, MA, PhD

Blood (2016) 128 (22): 418.

https://doi.org/10.1182/blood.V128.22.418.418

Published: 2016

Journal Articles

Pharmacokinetics (PK) and Pharmacodynamics (PD), Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Etexilate Given after Standard Anticoagulant Therapy in Children from Birth to Less Than One Year Old, with Venous Thromboembolism

Jacqueline ML Halton, MD, Anne-Caroline Picard, Ruth Harper, Fenglei Huang, Martina Brueckmann, MD, Savion Gropper, MD, Hugo Maas, Igor Tartakovsky, MD, Ildar Nurmeev, Lesley G Mitchell, Leonardo R. Brandão, MD MSc, Manuela Albisetti, MD

Blood (2016) 128 (22): 1441.

https://doi.org/10.1182/blood.V128.22.1441.1441

Published: 2016

Journal Articles

Dabigatran Is Associated with a Significantly Lower Risk of Abnormal Uterine Bleeding Than Warfarin in Female Patients of Childbearing Age with Venous Thromboembolism

Melanie Ferreira, Frederikus A Klok, Martin Feuring, Mandy Fraessdorf, Jörg Kreuzer, MD, Menno V Huisman

Blood (2016) 128 (22): 140.

https://doi.org/10.1182/blood.V128.22.140.140

Published: 2016

Journal Articles

Are Direct Oral Anticoagulants Plasma Concentrations Associated with the Risk of Postoperative Bleeding? Results from the Real Life Cohort

Pável Olivera, MD, Vicente Cortina, Verónica Pons, MD, Tania Canals, MD, Erik Johansson, MD, Francesc Bosch, MD PhD, Amparo Santamaría, MD PhD

Blood (2016) 128 (22): 3819.

https://doi.org/10.1182/blood.V128.22.3819.3819

Published: 2016

Journal Articles

Rationale and Design of a Phase III Safety Trial of Idarucizumab in Children Receiving Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism

Manuela Albisetti, MD, Arno Schlosser, MSc, Martina Brueckmann, MD, Savion Gropper, MD, Stephan Glund, PhD, Igor Tartakovsky, MD, Leonardo R. Brandão, MD MSc, Paul A Reilly, PhD

Blood (2016) 128 (22): 5010.

https://doi.org/10.1182/blood.V128.22.5010.5010

Published: 2016

Journal Articles

Rationale and Design of a Phase IIb/III Open-Label, Multicenter Study of Dabigatran Etexilate for Venous Thromboembolism in Children: The Diversity Study

Manuela Albisetti, MD, Ivan Manastirski, Martina Brueckmann, MD, Savion Gropper, MD, Bushi Wang, Igor Tartakovsky, MD, Branislav Biss, Fenglei Huang, Lesley G Mitchell, MSc, Leonardo R. Brandão, MD MSc, Jacqueline ML Halton, MD

Blood (2016) 128 (22): 5025.

https://doi.org/10.1182/blood.V128.22.5025.5025

Published: 2016

NARROW

Bleeding Risk in Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies

Efficacy and Safety of Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism

Effectiveness and Safety of Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Patients with Active Cancer Therapy and Non Valvular Atrial Fibrillation

Efficacy and Safety of Direct Oral Anticoagulants in Patients with Cirrhosis— Single Institution Experience

Risk of Subsequent Thrombosis in Patients with Isolated Heparin-Induced Thrombocytopenia

Heparin Vs Direct Thrombin Inhibitors in Patients with Previous HIT Undergoing Cardiothoracic Surgery: The Cleveland Clinic Experience

Comparison of Rivaroxaban with Argatroban in Heparin Induced Thrombocytopenia Using Historical Controls : A Case-Control Study

Yearly Percent Incidence of Suspected Novel Oral Anticoagulant Interference on Thrombophilia Testing: A Nine Year Experience at a Reference Coagulation Laboratory

Risk Factors for Thrombosis in the Neonatal Intensive Care Unit: Analysis of a Large National Database

Measuring the Anticoagulation Effects of Exosite I Thrombin Inhibitors: Utility and Limitations of Clotting Assays, Thromboelastography, and Calibrated Automated Thrombography

HIT Diagnosis: A Proposed New Definition for Clinical Research

Impact of Systems-Based Hematologists in Maintaining a HIT Program Using Continuous Clinical Audit and Education in an Academic Medical Center

A Simulation Analysis to Evaluate the Effect of Prospective Biomarker Testing on Progression-Free Survival (PFS) in DLBCL

HIT the price point with fondaparinux

Use of "Big Data" to Define Disease Burden, Complication Rates and Healthcare Costs in Patients with Heparin Induced Thrombocytopenia (HIT)

Pharmacokinetics (PK) and Pharmacodynamics (PD), Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Etexilate Given after Standard Anticoagulant Therapy in Children from Birth to Less Than One Year Old, with Venous Thromboembolism

Dabigatran Is Associated with a Significantly Lower Risk of Abnormal Uterine Bleeding Than Warfarin in Female Patients of Childbearing Age with Venous Thromboembolism

Are Direct Oral Anticoagulants Plasma Concentrations Associated with the Risk of Postoperative Bleeding? Results from the Real Life Cohort

Rationale and Design of a Phase III Safety Trial of Idarucizumab in Children Receiving Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism

Rationale and Design of a Phase IIb/III Open-Label, Multicenter Study of Dabigatran Etexilate for Venous Thromboembolism in Children: The Diversity Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only